Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| 3-Hydroxybutyric Acid | 1 | 2026 | 3 | 0.980 |
Why?
|
| Blood Gas Analysis | 1 | 2026 | 29 | 0.970 |
Why?
|
| Lactic Acid | 1 | 2026 | 79 | 0.920 |
Why?
|
| Genetic Predisposition to Disease | 5 | 2014 | 525 | 0.610 |
Why?
|
| Genetic Association Studies | 2 | 2014 | 124 | 0.510 |
Why?
|
| Breast Neoplasms | 2 | 2014 | 1203 | 0.460 |
Why?
|
| Phosphatidylcholine-Sterol O-Acyltransferase | 1 | 2014 | 1 | 0.440 |
Why?
|
| Cholesterol Ester Transfer Proteins | 1 | 2014 | 1 | 0.440 |
Why?
|
| Behcet Syndrome | 1 | 2014 | 7 | 0.430 |
Why?
|
| CTLA-4 Antigen | 1 | 2014 | 32 | 0.430 |
Why?
|
| Estrogen Receptor alpha | 1 | 2014 | 86 | 0.420 |
Why?
|
| Hyperlipidemias | 1 | 2014 | 52 | 0.420 |
Why?
|
| DNA Methylation | 2 | 2014 | 573 | 0.410 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2013 | 89 | 0.390 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2013 | 127 | 0.390 |
Why?
|
| Promoter Regions, Genetic | 1 | 2014 | 465 | 0.380 |
Why?
|
| Egypt | 4 | 2014 | 21 | 0.350 |
Why?
|
| DNA | 1 | 2014 | 544 | 0.350 |
Why?
|
| Coronary Artery Disease | 1 | 2014 | 323 | 0.320 |
Why?
|
| Multiple Myeloma | 1 | 2023 | 3013 | 0.300 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2014 | 506 | 0.260 |
Why?
|
| Middle Aged | 7 | 2026 | 13133 | 0.250 |
Why?
|
| False Positive Reactions | 1 | 2026 | 64 | 0.240 |
Why?
|
| Diabetic Ketoacidosis | 1 | 2026 | 17 | 0.240 |
Why?
|
| Blood Protein Electrophoresis | 1 | 2023 | 3 | 0.210 |
Why?
|
| Electrophoresis | 1 | 2023 | 16 | 0.210 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2026 | 202 | 0.210 |
Why?
|
| Immunoglobulin G | 1 | 2023 | 193 | 0.200 |
Why?
|
| Liver Failure, Acute | 1 | 2023 | 56 | 0.190 |
Why?
|
| Male | 8 | 2026 | 26874 | 0.190 |
Why?
|
| End Stage Liver Disease | 1 | 2023 | 52 | 0.190 |
Why?
|
| Case-Control Studies | 3 | 2014 | 1202 | 0.190 |
Why?
|
| Female | 9 | 2026 | 28277 | 0.180 |
Why?
|
| Humans | 11 | 2026 | 52441 | 0.170 |
Why?
|
| Adult | 6 | 2014 | 14205 | 0.160 |
Why?
|
| Antibodies, Monoclonal | 1 | 2023 | 475 | 0.160 |
Why?
|
| Risk | 2 | 2014 | 315 | 0.130 |
Why?
|
| Polymorphism, Genetic | 2 | 2013 | 184 | 0.120 |
Why?
|
| Adult Stem Cells | 1 | 2015 | 11 | 0.110 |
Why?
|
| Matrix Metalloproteinase 3 | 1 | 2014 | 19 | 0.110 |
Why?
|
| Joints | 1 | 2014 | 19 | 0.110 |
Why?
|
| CpG Islands | 1 | 2014 | 111 | 0.110 |
Why?
|
| Gene Frequency | 1 | 2014 | 97 | 0.110 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2015 | 83 | 0.110 |
Why?
|
| Exons | 1 | 2014 | 101 | 0.110 |
Why?
|
| Receptors, Calcitriol | 1 | 2013 | 18 | 0.110 |
Why?
|
| Receptors, IgG | 1 | 2013 | 22 | 0.110 |
Why?
|
| DNA Mutational Analysis | 1 | 2014 | 179 | 0.100 |
Why?
|
| Lupus Nephritis | 1 | 2013 | 18 | 0.100 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2013 | 65 | 0.100 |
Why?
|
| Vitamin D | 1 | 2013 | 86 | 0.100 |
Why?
|
| Doxorubicin | 1 | 2015 | 246 | 0.100 |
Why?
|
| Hepatitis C, Chronic | 1 | 2012 | 86 | 0.090 |
Why?
|
| Epigenesis, Genetic | 1 | 2013 | 396 | 0.080 |
Why?
|
| Aged | 1 | 2023 | 10242 | 0.080 |
Why?
|
| Cytokines | 1 | 2012 | 622 | 0.080 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2013 | 853 | 0.080 |
Why?
|
| Apoptosis | 1 | 2015 | 1120 | 0.080 |
Why?
|
| Mutation | 1 | 2014 | 1331 | 0.070 |
Why?
|
| Severity of Illness Index | 2 | 2023 | 1045 | 0.060 |
Why?
|
| Alleles | 2 | 2013 | 279 | 0.050 |
Why?
|
| Risk Assessment | 1 | 2023 | 1349 | 0.040 |
Why?
|
| Prognosis | 1 | 2023 | 2100 | 0.030 |
Why?
|
| Seminiferous Tubules | 1 | 2015 | 2 | 0.030 |
Why?
|
| Sperm Retrieval | 1 | 2015 | 2 | 0.030 |
Why?
|
| Caspase 8 | 1 | 2015 | 9 | 0.030 |
Why?
|
| Sperm Count | 1 | 2015 | 9 | 0.030 |
Why?
|
| Fas Ligand Protein | 1 | 2015 | 16 | 0.030 |
Why?
|
| Sperm Motility | 1 | 2015 | 13 | 0.030 |
Why?
|
| Glutathione Peroxidase | 1 | 2015 | 23 | 0.030 |
Why?
|
| Malondialdehyde | 1 | 2015 | 54 | 0.030 |
Why?
|
| Spermatozoa | 1 | 2015 | 29 | 0.030 |
Why?
|
| Caspase 3 | 1 | 2015 | 91 | 0.030 |
Why?
|
| Catalase | 1 | 2015 | 72 | 0.030 |
Why?
|
| Blood Sedimentation | 1 | 2014 | 16 | 0.030 |
Why?
|
| Superoxide Dismutase | 1 | 2015 | 120 | 0.030 |
Why?
|
| Testis | 1 | 2015 | 74 | 0.030 |
Why?
|
| Enzyme Activation | 1 | 2015 | 269 | 0.030 |
Why?
|
| Health Status Indicators | 1 | 2014 | 81 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2014 | 234 | 0.030 |
Why?
|
| Inflammation Mediators | 1 | 2014 | 113 | 0.030 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2014 | 114 | 0.030 |
Why?
|
| Oxidation-Reduction | 1 | 2015 | 327 | 0.030 |
Why?
|
| NF-kappa B | 1 | 2015 | 326 | 0.030 |
Why?
|
| Interferons | 1 | 2012 | 38 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2014 | 462 | 0.020 |
Why?
|
| Interleukins | 1 | 2012 | 34 | 0.020 |
Why?
|
| Interleukin-10 | 1 | 2012 | 81 | 0.020 |
Why?
|
| Gene Expression | 1 | 2015 | 618 | 0.020 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2012 | 61 | 0.020 |
Why?
|
| Genotype | 1 | 2013 | 563 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2014 | 938 | 0.020 |
Why?
|
| Disease Progression | 1 | 2014 | 870 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2012 | 390 | 0.020 |
Why?
|
| Oxidative Stress | 1 | 2015 | 805 | 0.020 |
Why?
|
| Rats | 1 | 2015 | 3228 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2014 | 2433 | 0.020 |
Why?
|
| Time Factors | 1 | 2014 | 2987 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2015 | 1724 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2014 | 1507 | 0.020 |
Why?
|
| Adolescent | 1 | 2013 | 6713 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2012 | 5508 | 0.010 |
Why?
|
| Child | 1 | 2013 | 7194 | 0.010 |
Why?
|
| Animals | 1 | 2015 | 13485 | 0.010 |
Why?
|